Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi Biologics (Cayman)'s Total Assets for the quarter that ended in Dec. 2025 was MXN162,839 Mil.
During the past 12 months, WuXi Biologics (Cayman)'s average Total Assets Growth Rate was 7.30% per year.
During the past 3 years, the average Total Assets Growth Rate was 5.10% per year.
During the past 5 years, the average Total Assets Growth Rate was 14.00% per year.
During the past 10 years, the average Total Assets Growth Rate was 49.40% per year.
During the past 12 years, WuXi Biologics (Cayman)'s highest 3-Year average Total Assets Growth Rate was 94.40%. The lowest was 5.10%. And the median was 61.10%.
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
WuXi Biologics (Cayman)'s Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
WuXi Biologics (Cayman) Total Assets Related Terms
WuXi Biologics (Cayman) Total Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
WuXi Biologics (Cayman)'s Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) (MEX:2269N) has a Total Assets of MXN162,839 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on WuXi Biologics (Cayman) and its competitors.
Is WuXi Biologics (Cayman)'s Total Assets too high?
WuXi Biologics (Cayman)'s current Total Assets is MXN162,839 Mil. Overall, WuXi Biologics (Cayman) has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Total Assets compare to VRTX and REGN?
WuXi Biologics (Cayman)'s Total Assets of MXN162,839 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on WuXi Biologics (Cayman) and its competitors. WuXi Biologics (Cayman)'s current Total Assets is MXN162,839 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
WuXi Biologics (Cayman) (MEX:2269N) has a current Total Assets of MXN162,839 Mil. The stock's GF Value™ is MXN54.50, compared to a current price of MXN62.53 — trading 14.7% above its estimated fair value. The current Total Assets is MXN162,839 Mil. WuXi Biologics (Cayman)'s overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For WuXi Biologics (Cayman) (MEX:2269N), the current Total Assets is MXN162,839 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (MEX:2269N) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be overvalued.
The current stock price of MXN62.53 is trading 14.7% above its estimated GF Value™ of MXN54.50.
Key valuation signals for MEX:2269N:
Total Assets: MXN162,839 Mil
GF Value™: MXN54.50 vs. price of MXN62.53 (14.7% above fair value)
No single metric tells the full story. See the MEX:2269N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
97GF Score
Get the complete analysis for MEX:2269N
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:2269N has been successfully added to your 
